



Bristol-Myers Squibb Company
Patent Department

FAX RECEIVED

AUG 01 2003

GROUP 1600

FACSIMILE TRANSMITTAL SHEET

TO: Examiner V. Balasubramanian
COMPANY: Art Unit 1624 -USPTO
FAX NO.: 703-308-4556
FROM: Laurelee Duncan
TELEPHONE NO.: 609-252-5323
FACSIMILE NO.: (609) 252-4526
DATE: July 30th, 2003
RE: Unsigned Amendment
Number of Pages: 24 (including cover sheet)

OFFICIAL

COMMENTS:

In response to your Office Communication dated July 25, 2003, I am now faxing the signed Amendment of July 5th for the record.

This document contains privileged client-attorney communications. The information is intended to be for the use of the addressee only. If you are not the addressee, note that any disclosure, copy, distribution or use of the contents of this document is prohibited. If you have received this message in error, please notify the sender of the error and delete the message. Thank you.

Duplicate

BY FACSIMILE

CASE QA0239A CIP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Laurelee A. Duncan

Type or print name

Laurelee A. Duncan

Signature

May 5, 2003

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1624

MORIARTY ET AL.

Examiner: V. Balasubramanian

APPLICATION NO: 09/891,750

FILED: JUNE 26, 2001

FOR: N-HETEROCYCLIC INHIBITORS OF TNF-ALPHA EXPRESSION

Assistant Commissioner for Patents
Washington, D.C. 20231

AMENDMENT

Sir:

In response to the Office Action mailed December 3, 2002, having a shortened statutory time set to expire on March 3, 2003, please enter the following amendment and consider the Remarks below.